RadNet, Inc. RDNT R2KR3KPHARMA

Q: What is the current share price of RadNet, Inc. (RDNT)?

As of 2026-10-22 16:30 PDT, RadNet, Inc. (RDNT) trades at $70.26 on NasdaqGM. Its 52-week range is $51.87 to $84.48.

Q: What is the market capitalisation of RDNT?

RadNet, Inc. (RDNT) has a market capitalisation of $5.53B on NasdaqGM.

Q: What is the P/E ratio of RDNT?

RDNT trades at a trailing price-to-earnings (P/E) ratio of -270.23. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 5.52.

Q: What is the return on equity (ROE) of RDNT?

RDNT has a return on equity (ROE) of 1.50%. Its return on capital employed (ROCE) is 1.95%.

Q: Is RDNT a good stock to buy?

This page provides a data-driven analysis of RadNet, Inc. (RDNT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Diagnostics & Research · United States

https://www.radnet.com

Company Profile ↓

$70.26

+2.70% 1Y

Mkt Cap$5.53B

P/E-270.23

P/B5.52

52W High$84.48

52W Low$51.87

Book Value$13.76

EPS (TTM)$-0.26

Company Overview

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretations of breast, lung, and prostate images, as well as solutions for prostate cancer screening. In addition, it develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology; informatics designed for outpatient radiology; and DeepHealth OS, a cloud-native operating system that helps in the operations of the radiology service. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $2.04B (+11.5% YoY); net profit $-18.65M.
Trailing 12 Months Year-on-year growth — revenue +25.0%, earnings -49.1%.
5-Year Trend Long-term compounding — revenue CAGR 8.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	8.82%
1 Year:	25.00%

Compounded Profit Growth

5 Years:	-
1 Year:	-49.10%

Stock Price Performance

1 Year:	+2.70%
6 Months:	+24.49%
3 Months:	+14.11%
1 Month:	-4.03%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed

52-Week Range 56% of range

$51.87 $84.48

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMAAbove
RSI (14)48.72 · Neutral

Price Performance

1M-4.03%

3M+14.11%

6M+24.49%

1Y+2.70%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-270.23

Industry PE

25.61

Forward P/E

79.24

PEG Ratio

0.96

Book Value

$13.76

Price to Book

5.52

P/S

2.64

EV/EBITDA

28.02

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

8.82%

Profit 5Y

Revenue (YoY)

25.00%

Earnings (YoY)

-49.10%

Profitability & Returns

ROCE

1.95%

ROE

1.50%

ROA

1.70%

Profit Margin

-0.93%

Op Margin

7.89%

Gross Margin

17.28%

EPS (Latest Qtr)

$0.10

EPS (TTM)

$-0.26

Balance Sheet & Liquidity

Debt/Equity

1.57

Quick Ratio

1.39

Current Ratio

1.48

Debt

$2.18B

Total Assets

$4.23B

Current Assets

$740.77M

Working Capital

$445.36M

Ownership

Promoter Holding

9.96%

Chg in Prom Hold

-0.01%

FII / Inst Holding

105.55%

Chg in FII Hold

0.16%

Financial Snapshot

Enterprise Value

$5.53B

Total Revenue (TTM)

$2.27B

EBITDA

$276.15M

Free Cash Flow

$157.74M

Operating Cash Flow

$310.06M

Shares Outstanding

78.70M

Gross Margin

17.28%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	RDNT RadNet, Inc. R2KR3KPHARMA	70.26	-270.23	$5.53B	0.00%	1.95%	1.50%	8.82%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,306.69	43.95	$1.16T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	267.61	31.05	$644.91B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	285.19	80.56	$503.96B	2.54%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	424.98	27.29	$381.46B	2.47%	9.74%	14.15%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPXR3KPHARMA	147.24	117.79	$363.27B	2.31%	-	6.96%	5.64%	10.01%
7	NVS Novartis AG PHARMA	156.27	23.61	$297.02B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	172.57	25.80	$267.64B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	676.54	36.45	$250.15B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	289.10M	292.69M	-	281.56M	190.57M	291.78M	315.32M	333.92M	332.69M	341.77M	354.38M	350.04M	390.56M	403.71M	401.97M	431.71M	459.71M	461.14M	471.40M	498.23M	522.87M	575.63M	622.72M
Operating Income	-1.95M	13.38M	17.23M	-	2.98M	8.08M	12.45M	-	6.75M	14.16M	10.84M	-	-888.00K	15.87M	16.45M	-	7.27M	21.98M	16.85M	-	-8.78M	179.00K	23.38M	17.65M	27.68M	32.57M	-1.72M	19.56M	6.92M	6.67M	24.44M	43.25M	11.34M	34.85M	33.91M	-24.10M	30.88M	27.39M	-23.90M	39.47M
Net Income	-4.55M	3.40M	7.99M	881.00K	-1.72M	3.62M	1.65M	3.68M	-1.21M	5.31M	3.23M	-7.28M	-7.34M	5.41M	5.04M	29.14M	-3.73M	4.90M	3.19M	10.40M	-16.36M	-10.59M	6.16M	9.46M	2.87M	16.22M	3.01M	7.91M	668.00K	-21.00M	8.37M	17.54M	-2.78M	-2.98M	3.21M	-37.93M	14.45M	5.42M	-33.47M	7.53M
Diluted EPS	-0.11	0.08	0.18	0.02	-0.04	0.08	0.04	0.08	-0.03	0.11	0.07	-0.15	-0.15	0.11	0.10	0.59	-0.08	0.10	0.06	0.21	-0.33	-0.21	0.12	0.18	0.05	0.30	0.05	0.13	0.01	-0.36	0.12	0.25	-0.04	-0.04	0.04	-0.51	0.19	0.07	-0.43	0.10

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	527.62M	76.94M	76.08M	85.04M	702.99M	717.57M	809.63M	884.53M	922.19M	975.15M	1.15B	1.07B	1.32B	1.43B	1.62B	1.83B	2.04B
Operating Income	42.10M	41.71M	50.66M	12.64M	43.60M	53.30M	39.12M	38.48M	50.05M	30.89M	69.88M	35.68M	82.55M	46.36M	98.70M	104.62M	61.99M
Net Income	-2.27M	-12.85M	7.23M	12.39M	2.12M	1.38M	7.71M	7.23M	53.00K	32.24M	14.76M	-14.84M	24.73M	10.65M	3.04M	2.79M	-18.65M
Diluted EPS	-0.06	-0.35	0.19	1.52	0.05	0.03	0.17	0.15	0.00	0.66	0.29	-0.29	0.46	0.17	0.05	0.04	-0.25

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	539.51M	619.19M	710.86M	40.65M	740.68M	836.43M	849.48M	868.98M	1.11B	1.65B	1.79B	-	2.43B	2.69B	3.29B	3.76B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	367.18M	579.28M	1.02B	1.03B
Cash & Equivalents	-	10.09M	627.00K	2.09M	362.00K	8.41M	307.00K	446.00K	20.64M	51.32M	10.39M	40.16M	102.02M	-	127.83M	342.57M	740.02M	767.22M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	166.36M	163.71M	185.82M	200.32M
Total Liabilities	-	-	621.99M	689.00M	717.55M	5.64M	732.98M	799.97M	797.42M	799.05M	909.08M	1.41B	1.53B	-	1.94B	1.88B	2.15B	2.40B
Current Liabilities	-	-	105.26M	122.38M	119.04M	2.98M	133.27M	156.96M	155.34M	191.61M	239.52M	327.43M	398.11M	-	466.72M	437.45M	479.71M	586.76M
Long Term Debt	-	-	-	543.19M	573.76M	575.45M	572.50M	607.61M	612.17M	575.04M	-	-	612.91M	-	839.34M	812.07M	991.57M	1.06B
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.51B	1.49B	1.73B	1.86B
Total Equity	-81.03M	-74.76M	-82.47M	-69.81M	-6.68M	-80.00K	7.70M	36.46M	52.05M	61.56M	127.18M	151.69M	165.74M	-	333.00M	630.70M	902.31M	1.09B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	57.72M	67.96M	74.04M	77.40M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	76.62M	66.88M	57.64M	75.27M	66.42M	-	67.04M	91.64M	142.22M	116.75M	104.32M	233.76M	149.49M	146.42M	220.86M	233.02M	298.82M
Investing Cash Flow	-36.28M	-101.38M	-87.74M	-87.05M	-50.66M	-	-96.80M	-65.49M	-79.32M	-146.75M	-99.47M	-126.24M	-221.51M	-246.95M	-201.47M	-233.07M	-343.87M
Financing Cash Flow	-30.24M	25.04M	31.93M	9.62M	-7.62M	-	29.94M	-5.91M	-32.25M	-10.87M	24.95M	-45.56M	104.67M	93.65M	195.63M	397.95M	72.21M
Capital Expenditure	-30.75M	-40.29M	-42.72M	-1.09M	-48.62M	-41.74M	-42.96M	-59.25M	-61.34M	-72.18M	-74.15M	-	-	-	-	-	-
Free Cash Flow	45.87M	26.59M	14.92M	74.18M	17.80M	-	24.07M	32.39M	80.89M	44.57M	30.17M	-	-	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	8.0%	54.2%	66.6%	14.9%	6.2%	7.4%	4.8%	4.4%	5.4%	3.2%	6.1%	3.3%	6.3%	3.2%	6.1%	5.7%	3.0%
Net Margin %	-0.4%	-16.7%	9.5%	14.6%	0.3%	0.2%	1.0%	0.8%	0.0%	3.3%	1.3%	-1.4%	1.9%	0.7%	0.2%	0.2%	-0.9%
ROE %	3.0%	15.6%	-10.4%	-185.4%	-2,650.0%	17.9%	21.1%	13.9%	0.1%	25.4%	9.7%	-9.0%	-	3.2%	0.5%	0.3%	-1.7%
ROCE %	-	9.6%	10.2%	2.1%	115.8%	8.8%	5.8%	5.5%	7.4%	3.6%	5.3%	2.6%	-	2.4%	4.4%	3.7%	2.0%

Shareholding Pattern

Insiders

9.96%

Institutions

105.55%

Public Float

117.22%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	13.92%	10.96M	$777.02M
2	RTW Investments LP	6.16%	4.85M	$343.70M
3	Price (T.Rowe) Associates Inc	5.72%	4.50M	$319.18M
4	Vanguard Portfolio Management LLC	5.17%	4.07M	$288.39M
5	Vanguard Capital Management LLC	4.06%	3.19M	$226.46M
6	Beck, Mack & Oliver LLC	4.02%	3.16M	$224.33M
7	State Street Corporation	3.61%	2.84M	$201.56M
8	Geode Capital Management, LLC	2.36%	1.86M	$131.79M
9	Invesco Ltd.	2.09%	1.64M	$116.38M
10	American Century Companies Inc	2.06%	1.62M	$114.76M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for RDNT

Google News Wed, 21 Oct 2026

RadNet, Inc. (RDNT) Stock Forecasts - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxOVlZNUmIwUVRuU0VFSGpXblZ5T0NxbTZic25vTFRrU0FTZklFN0I0MWRvYmhldVdKSlVlWGphc3FtYzh1NHF6WEpCNTJfYmQyZktnZnlRMDFobFRJd3JWSnVXdnNscDZnLXd6MTdBRF96UEdpd2VXRFdhVmpIbi11eEhhVG1KOENPUTl6R2…

Google News ue, 13 Oct 2026

Here’s How Much You Would Have Made Owning RadNet Stock In The Last 15 Years - Benzinga

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQM0FhTTRRQWs1aDJwSFAtYWJyZFRjLWlab0xoYjI4X1ZLZFl3UFpWX3hsNnBkRkRRVldwMS1YTk9PY1FuT1NKNWJabjRUa1dkaXJnR25zZTN5bTlBdzZQZkF6ZndlSk9pM0xxblNjallHMDRWeVJsS0tWS0lYZUwxR0xwcGh1Z1hncWlfSU…

Google News Mon, 19 Oct 2026

Earnings Beat Might Change The Case For Investing In RadNet Stock (RDNT) - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQTm5NMFRISFBSNVB4OTFfSEcxWjVMWmxQdG9PbW1HbEkxb1lZZHJiNEtySHhONW1NbVJtR0lkRzlSWlM0Z3NnSm1VVWtwQmNyWUVTYjZLcC15c0JWV2ZiVXlSaXZOUGN3S01yanZJRWMtbW9OQ1RpaVNUUDRuU3lnNHZkaHB6MXY2NG9ZeT…

Google News Sat, 07 Mar 2026

RadNet Stock To $42? - Trefis

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxPYkx4V1M5UE5DQThiR2lXRXRIZHF1aGE4SDFYUmU0MWc0VE1ZY0YyeGc3RXRsb2I1UVdraHpONnB4UlV4UWRUTmhSV2h2OTA5WHpPMlFnZ0c3YW8tbFZkTHIzbW9SblF0c3ZSa2NmQ3F0d3ctSHdFWGd4ckJFaWlDOVVXYk9YYUU?oc=5" …

Google News Wed, 17 Jun 2026

Why RadNet (RDNT) Stock Is Down Today - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOc1pxOXM0Y1UtWFA0UmNaTzZNdFpUSG1TN3RUNEh6MGlpQ2Y4U1FCR3VPajN6Qkd3aDNKWllfNHdnNldDTVVMMjNBQ1V5VlYzTGRpSjMtVVlGbVpzQlBNTVdyZVlRc2sxLWR2cFVxVVNjV2V4aHpIQ2MzcUVMdzhhTmNvSGI3aXZXU1ROTX…

Google News Mon, 14 Sep 2026

RadNet (RDNT) Stock May Be 23% Below Fair Value On Cash Flow - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxONzRzU2ZuVmI2LTNERUNDbU5MM1FmRjRfa2ZZY2RWclRHcXZ0Y1h4cW92SGI4N2Y1VzdWT1NYWEZraXhaVE42ajVMNXNWV3VJLTNSOUUwQWdLSUV3NDhzTW1RZ2dvN3loTUw1NmRSdnh0a3BfcjFJYkItOHg4VTVYOExSRmV1RjFTMG03LW…

RDNT — Frequently Asked Questions

What is the current share price of RadNet, Inc. (RDNT)?

As of 2026-10-22 16:30 PDT, RadNet, Inc. (RDNT) trades at $70.26 on NasdaqGM. Its 52-week range is $51.87 to $84.48.

What is the market capitalisation of RDNT?

RadNet, Inc. (RDNT) has a market capitalisation of $5.53B on NasdaqGM.

What is the P/E ratio of RDNT?

RDNT trades at a trailing price-to-earnings (P/E) ratio of -270.23. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 5.52.

What is the return on equity (ROE) of RDNT?

RDNT has a return on equity (ROE) of 1.50%. Its return on capital employed (ROCE) is 1.95%.

Is RDNT a good stock to buy?

This page provides a data-driven analysis of RadNet, Inc. (RDNT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

RadNet, Inc. RDNT R2KR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

RadNet, Inc. (RDNT) Stock Forecasts - Yahoo Finance

Here’s How Much You Would Have Made Owning RadNet Stock In The Last 15 Years - Benzinga

Earnings Beat Might Change The Case For Investing In RadNet Stock (RDNT) - Simply Wall Street

RadNet Stock To $42? - Trefis

Why RadNet (RDNT) Stock Is Down Today - Yahoo Finance

RadNet (RDNT) Stock May Be 23% Below Fair Value On Cash Flow - Yahoo Finance

RDNT — Frequently Asked Questions

What is the current share price of RadNet, Inc. (RDNT)?

What is the market capitalisation of RDNT?

What is the P/E ratio of RDNT?

What is the return on equity (ROE) of RDNT?

Is RDNT a good stock to buy?

Explore More